Australia's Neuren Pharma gains on FDA nod for phase-2 trial of PMS drug

Neuren Pharmaceuticals

23/03/2022 03:16

** Shares of biopharma co Neuren Pharmaceuticals  NEU.AX 
rise as much as 5.5% to A$4.41 
    ** Co says it received approval from the U.S. Food and Drug
Administration (FDA) to go ahead with phase-2 trial of drug
NNZ-2591 in Phelan-McDermid Syndrome (PMS)  urn:newsml:reuters.com:*:nASX9dThCL
    ** PMS is a rare genetic condition that causes development
and speech delays, behavioral problems, among others    
    ** Co says results from the trial are anticipated in H1 2023
    ** Stock up 10.9% this year, as of last close

 (Reporting by Jaskiran Singh in Bengaluru)
 ((Jaskiran.Singh@thomsonreuters.com;))